Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 5, 2008, Pages 470-473

  Ecke, Thorsten H ^a   Schlechte, Horst H ^b   Gunia, Sven ^a   Lenk, Severin V ^b   Loening, Stefan A ^b  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bladder cancer; Body mass index; Mutation; TP53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; BODY MASS; BODY WEIGHT; CANCER GRADING; CANCER RISK; CANCER STAGING; CORRELATION COEFFICIENT; EXON; FEMALE; GEL ELECTROPHORESIS; GENE MUTATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TP53 GENE; TUMOR SUPPRESSOR GENE;

AGED; BODY MASS INDEX; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; OBESITY; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 50649095182     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.12.005     Document Type: Article

References (34)

1. Burchardt M., Burchardt T., Shabsigh A., et al. Current concepts in biomarker technology for bladder cancers. Clin Chem 46 (2000) 595-605
2. Ecke T.H., Schlechte H.H., Schulze G., et al. Four tumor markers for urinary bladder cancer-tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR), and TP53 mutation. Anticancer Res 25 (2005) 635-641
3. Kroft S.H., and Oyasu R. Biology of disease; urinary bladder cancer: Mechanisms of development and progression. Lab Invest 71 (1994) 158-174
4. Sanchez-Carbayo M. Recent advances in bladder cancer diagnostics. Clin Biochem 37 (2004) 562-571
5. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 160 (1998) 645-659
6. Brauers A., and Jakse G. Die Bedeutung zytogenetischer und molekularbiologischer Veränderungen bei der Entwicklung und Prognose des Harnblasenkarzinoms. In: Schnorr D., Loening S.A., and Guddat H.-M. (Eds). Das Harnblasenkarzinom (1996), Logos Verlag, Berlin 1-32
7. Mokdad A.H., Bowman B.A., Ford E.S., et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195
8. Deurenberg P., Westsrate J.A., and Seidell J.C. Body mass index as a measure of body fatness: Age- and sex-specific prediction formulas. Br J Nutr 65 (1991) 105
9. Spruck III C.H., Rideout III W.M., Olumi A.F., et al. Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 53 (1993) 1162-1166
10. McBride O.W., Merry D., and Givol D. The gen for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83 (1986) 130-134
11. Miller C., Mohandas T., Wolf D., et al. Human p53 localized to short arm of chromosome 17. Nature 319 (1986) 783-784
12. Harris C.C. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer 88 (1996) 1442-1455
13. Lowe S.W., Schmitt S.W., Smith S.W., et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
14. Symonds H., Krall L., Remington L., et al. p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78 (1994) 703-711
15. Ozbun M.A., and Butel J.S. p53 Tumor suppressor gene: Structure and function. In: Bertino J.R. (Ed). The Encyclopedia of Cancer Vol. II (1997), Academic Press, New York 1240-1257
16. Sidransky D., von Eschenbach A., Tsai Y.C., et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252 (1991) 706-709
17. Schlechte H.H., Schnorr D., Löning T., et al. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers investigation by temperature gradient gel electrophoresis (TGGE). J Urol 157 (1997) 1049-1053
18. Brenner S., Schlechte H., Lenk S., et al. Experiments of bladder cancer on the basis of urine analysis-Tp53-mutation in cellular urine sediment. J Urol 155 (1996) 690A
19. Zhang Z.F., Zeng Z.S., Sarkis A.S., et al. Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer. Br J Cancer 71 (1995) 888-893
20. Moller H., Mellemgaard A., Lindvig K., et al. Obesity and cancer risk: A Danish record-linkage study. Eur J Cancer 30A (1994) 344
21. Wolk A., Gridley G., Svensson M., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12 (2001) 13
22. Pan S.Y., Johnson K.C., Ugnat A.M., et al. Canadian Cancer Registries Epidemiology Research Group: Association of obesity and cancer risk in Canada. Am J Epidemiol 159 (2004) 259
23. Samanic C., Gridley G., Chow W.H., et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15 (2004) 35
24. Holick C.N., Giovannucci E.L., Stampfer M.J., et al. Prospective study of body mass index, height, physical activity, and incidence of bladder cancer in U.S. men and women. Int J Cancer 120 (2006) 140-146
25. Metzger A., Sheffield K., Duyk V.C.G., et al. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci USA 88 (1991) 7825-7829
26. Hedrum A., Pontén F., Ren Z., et al. Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. Biotechniques 17 (1994) 118-129
27. Kusser W.C., Miao X., Glickman B.W., et al. p53 Mutations in human bladder cancer. Env Molec Mutagen 24 (1994) 156-160
28. Schlechte H.H., Sachs M.D., Lenk S.V., et al. Progression in transitional cell carcinoma of the urinary bladder-analysis of TP53 gene mutations by temperature gradient gel electrophoresis and sequencing in tumor tissues and in cellular urine sediments. Cancer Detect Prev 24 (2000) 24-32
29. Sidransky D., and Hollstein M. Clinical implications of the p53 gene. Ann Rev Med 47 (1996) 285-301
30. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85 (1993) 53-59
31. Fisher C.J., Gillet C.E., Vojtesk B., et al. Problems with p53 immunohistochemical staining: The effect of fixation and variation in the methods of evaluation. Br J Cancer 69 (1994) 26-31
32. Dalbagni G., Presti J.C., Reuter V., et al. Molecular genetic alteration of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagnost Mol Pathol 2 1 (1993) 4-13
33. Cordon-Cardo C., Dalbagni G., Saez G.T., et al. p53 Mutations in human bladder cancer: Genotypic vs. phenotypic pattern. Int J Cancer 56 (1994) 347-353
34. Hafron J., Mitra N., Dalbagni G., et al. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer?. J Urol 173 (2005) 1513-1517